Nothing written yet for this company.
Onconic Therapeutics, Inc. (476060) received Korean approval for a phase 3 trial of zastaprazan, Newsis reported Thursday.
| Period | 476060 | KOSDAQ | Difference |
|---|---|---|---|
| 1 week | +11.3% | -3.0% | +14.3% |
| 1 month | +30.0% | +4.2% | +25.8% |
| 3 months | -1.4% | -22.5% | +21.1% |
| 6 months | -5.0% | -16.9% | +11.9% |
| Year to date | -15.9% | -12.1% | -3.8% |
| 1 year | +115.3% | +1.0% | +114.3% |
Closed at 47% of the way from its 52-week low (₩7,637) to its 52-week high (₩26,300).
Onconic Therapeutics, Inc. does research and development in science and engineering in South Korea. It is listed on KOSDAQ, was founded in 2020, is based in Seoul, and has revenue of tens of billions of won.
| Sector | Biopharma | Employees | |
| Market | KOSDAQ | Founded | 2020 |
| Korean name | 온코닉테라퓨틱스 | Head office | Seoul |
| Symbol | Last Price |
|---|---|
| 185750Chong Kun Dang Pharmaceutical Corp. | ₩68,000 -0.3% |
| 115180Qurient Co., Ltd. | ₩23,050 +17.3% |
| 476830Rznomics, Inc. | ₩28,200 +6.8% |
| 003850Boryung Corporation | ₩9,040 +1.6% |
| 950260Ingenia Therapeutics Inc.(reg.s) | ₩15,580 -1.5% |
| 085660Chabiotech Co., Ltd. | ₩8,090 +2.1% |
| 041960Komipharm International Co., Ltd. | ₩9,710 +3.5% |
| 317450Myungin Pharm | ₩44,650 +0.0% |
| 001060JW Pharmaceutical | ₩27,500 +1.3% |
| 456160G2GBIO, Inc. | ₩37,950 +5.7% |